Factors Affecting the Efficacy and Safety of First-Line Anti-PD-1 Therapy in Advanced Non-Small Cell Lung CancerOA
Objective:This study assesses peripheral blood parameters as predictors of programmed cell death protein-1(PD-1)inhibitor efficacy in advanced non-small cell lung cancer(NSCLC).Methods:We retrospectively analyzed 169 advanced NSCLC patients receiving first-line PD-1 inhibitor-based therapy.Baseline blood parameters and clinical characteristicswere recorded.Logistic regression assessed associations with immune-related adverse events(irAEs).Chi-square tests compared efficacy and safety across treatment groups.Results:Baseline albumin/fibrinogen ratio(ALB/FIB)and PIV were associated with all-grade irAEs(p<0.05),while PIV was markedly associated with grade≥3 irAEs(p<0.01).Multivariate analysis identified that the baseline pan-immune inflammation value(PIV)was independently associated with the occurrence of irAEs(p<0.01).Compared to PD-1 inhibitor plus chemotherapy,adding bevacizumab increased oral mucositis(p=0.010)and was linked to a later clinical stage(p=0.001).In patients receiving peri-immunotherapy radiotherapy,leukopenia was more frequent(p=0.030).Conclusion:Baseline PIV is independently associated with the occurrence of irAEs in advanced NSCLC patients receiving first-line PD-1 inhibitor therapy.Adding bevacizumab or radiotherapy may modify safety profiles.
Zhen Wang;Qian Xie;Yu Luo;Chuan Li;Wenqiang Guan;Yanling Zhang;Jidong Miao
Department of Oncology,Zigong Fourth People’s Hospital,Ziliujing District,Zigong,ChinaSchool of Education and Sports,Sichuan Vocational College of Health and Rehabilitation,Yantian District,Zigong,ChinaDepartment of Critical Care,Qingdao Municipal Hospital,Shinan District,Qingdao,ChinaDepartment of Oncology,Zigong Fourth People’s Hospital,Ziliujing District,Zigong,ChinaDepartment of Oncology,Zigong Fourth People’s Hospital,Ziliujing District,Zigong,ChinaDepartment of Respiratory and Critical Care Medicine,Qingdao Municipal Hospital,Qingdao University,Shinan District,Qingdao,ChinaDepartment of Oncology,Zigong Fourth People’s Hospital,Ziliujing District,Zigong,China
医药卫生
Advanced non-small cell lung cancerPD-1 inhibitorssafetyimmune-related adverse eventsprognosis
《Oncology Research》 2026 (7)
P.651-665,15
评论